[ad_1]
The Sanofi and GlaxoSmithKline vaccine will not launch before the end of next year.
The vaccine from the European companies Sanofi and GlaxoSmithKline has shown insufficient efficacy in elderly patients.
The French company Sanofi and the British company GlaxoSmithKline have postponed the launch of their vaccine due to its lack of effectiveness. The modified vaccine will not be launched before the end of 2021. This is stated in a statement from the companies released on Friday, December 11.
It should be noted that the company made this decision after the drug under development did not show sufficient efficacy in elderly patients. The developers claimed that this may be due to insufficient concentration of antigen, a substance that elicits an immune response.
At the same time, studies have shown that people between the ages of 18 and 49 who received the vaccine had the same immune response as those who had had COVID-19.
The potential availability of the vaccine has been delayed until the fourth quarter of 2021, although it was previously expected to arrive in the first half of the year.
“Product availability is now expected in the fourth quarter of 2021, pending the successful completion of the development plan,” the statement said.
The news surprised many governments, including the EU, the US, Canada and the UK, which have reserved hundreds of millions of doses of the potential vaccine.
In summer, the UK authorities signed an agreement to supply 60 million doses of this vaccine.
Also in July, it was reported that the United States will allocate 2.1 billion dollars to the French pharmaceutical corporation Sanofi and Britain’s GlaxoSmithKline for the joint development of a vaccine against the coronavirus.
News of Correspondent.net on Telegram. Subscribe to our channel https://t.me/korrespondentnet
